Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 156

1.

Regulation of an Opioid Receptor Chaperone Protein, RTP4, by Morphine.

Fujita W, Yokote M, Gomes I, Gupta A, Ueda H, Devi LA.

Mol Pharmacol. 2019 Jan;95(1):11-19. doi: 10.1124/mol.118.112987. Epub 2018 Oct 22.

PMID:
30348895
2.

Targeting the Recently Deorphanized Receptor GPR83 for the Treatment of Immunological, Neuroendocrine and Neuropsychiatric Disorders.

Lueptow LM, Devi LA, Fakira AK.

Prog Mol Biol Transl Sci. 2018;159:1-25. doi: 10.1016/bs.pmbts.2018.07.002. Epub 2018 Aug 25.

PMID:
30340784
3.

Exploring Morphine-Triggered PKC-Targets and Their Interaction with Signaling Pathways Leading to Pain via TrkA.

Pena DA, Duarte ML, Pramio DT, Devi LA, Schechtman D.

Proteomes. 2018 Oct 6;6(4). pii: E39. doi: 10.3390/proteomes6040039. Review.

4.

Correction: Generation of G protein-coupled receptor antibodies differentially sensitive to conformational states.

Heimann AS, Gupta A, Gomes I, Rahman R, Schlessinger A, Ferro ES, Unterwald EM, Devi LA.

PLoS One. 2018 Feb 15;13(2):e0193322. doi: 10.1371/journal.pone.0193322. eCollection 2018.

5.

Strategy for making safer opioids bolstered.

Majumdar S, Devi LA.

Nature. 2018 Jan 18;553(7688):286-288. doi: 10.1038/d41586-018-00045-1. No abstract available. Erratum in: Nature. 2018 Feb 8;554(7691):181.

PMID:
29345640
6.

Orphan neuropeptides and receptors: Novel therapeutic targets.

Fricker LD, Devi LA.

Pharmacol Ther. 2018 May;185:26-33. doi: 10.1016/j.pharmthera.2017.11.006. Epub 2017 Nov 22. Review.

PMID:
29174650
7.

A novel peptide that improves metabolic parameters without adverse central nervous system effects.

Reckziegel P, Festuccia WT, Britto LRG, Jang KLL, Romão CM, Heimann JC, Fogaça MV, Rodrigues NS, Silva NR, Guimarães FS, Eichler RAS, Gupta A, Gomes I, Devi LA, Heimann AS, Ferro ES.

Sci Rep. 2017 Nov 1;7(1):14781. doi: 10.1038/s41598-017-13690-9.

8.

Generation of G protein-coupled receptor antibodies differentially sensitive to conformational states.

Heimann AS, Gupta A, Gomes I, Rayees R, Schlessinger A, Ferro ES, Unterwald EM, Devi LA.

PLoS One. 2017 Nov 1;12(11):e0187306. doi: 10.1371/journal.pone.0187306. eCollection 2017. Erratum in: PLoS One. 2018 Feb 15;13(2):e0193322.

9.

Two delta opioid receptor subtypes are functional in single ventral tegmental area neurons, and can interact with the mu opioid receptor.

Margolis EB, Fujita W, Devi LA, Fields HL.

Neuropharmacology. 2017 Sep 1;123:420-432. doi: 10.1016/j.neuropharm.2017.06.019. Epub 2017 Jun 21.

10.

The BigLEN-GPR171 Peptide Receptor System Within the Basolateral Amygdala Regulates Anxiety-Like Behavior and Contextual Fear Conditioning.

Bobeck EN, Gomes I, Pena D, Cummings KA, Clem RL, Mezei M, Devi LA.

Neuropsychopharmacology. 2017 Dec;42(13):2527-2536. doi: 10.1038/npp.2017.79. Epub 2017 Apr 20.

11.

Detection of Receptor Heteromerization Using In Situ Proximity Ligation Assay.

Gomes I, Sierra S, Devi LA.

Curr Protoc Pharmacol. 2016 Dec 13;75:2.16.1-2.16.31. doi: 10.1002/cpph.15.

12.

Identification of a small-molecule ligand that activates the neuropeptide receptor GPR171 and increases food intake.

Wardman JH, Gomes I, Bobeck EN, Stockert JA, Kapoor A, Bisignano P, Gupta A, Mezei M, Kumar S, Filizola M, Devi LA.

Sci Signal. 2016 May 31;9(430):ra55. doi: 10.1126/scisignal.aac8035.

13.

Collybolide is a novel biased agonist of κ-opioid receptors with potent antipruritic activity.

Gupta A, Gomes I, Bobeck EN, Fakira AK, Massaro NP, Sharma I, Cavé A, Hamm HE, Parello J, Devi LA.

Proc Natl Acad Sci U S A. 2016 May 24;113(21):6041-6. doi: 10.1073/pnas.1521825113. Epub 2016 May 9.

14.

Identification of GPR83 as the receptor for the neuroendocrine peptide PEN.

Gomes I, Bobeck EN, Margolis EB, Gupta A, Sierra S, Fakira AK, Fujita W, Müller TD, Müller A, Tschöp MH, Kleinau G, Fricker LD, Devi LA.

Sci Signal. 2016 Apr 26;9(425):ra43. doi: 10.1126/scisignal.aad0694.

15.

Rational design and validation of an anti-protein kinase C active-state specific antibody based on conformational changes.

Pena DA, Andrade VP, Silva GÁ, Neves JI, Oliveira PS, Alves MJ, Devi LA, Schechtman D.

Sci Rep. 2016 Feb 25;6:22114. doi: 10.1038/srep22114.

16.

G Protein-Coupled Receptor Heteromers.

Gomes I, Ayoub MA, Fujita W, Jaeger WC, Pfleger KD, Devi LA.

Annu Rev Pharmacol Toxicol. 2016;56:403-25. doi: 10.1146/annurev-pharmtox-011613-135952. Epub 2015 Oct 22. Review.

17.

Morphine Regulated Synaptic Networks Revealed by Integrated Proteomics and Network Analysis.

Stockton SD Jr, Gomes I, Liu T, Moraje C, Hipólito L, Jones MR, Ma'ayan A, Morón JA, Li H, Devi LA.

Mol Cell Proteomics. 2015 Oct;14(10):2564-76. doi: 10.1074/mcp.M115.047977. Epub 2015 Jul 6.

18.

Advancements in therapeutically targeting orphan GPCRs.

Stockert JA, Devi LA.

Front Pharmacol. 2015 May 8;6:100. doi: 10.3389/fphar.2015.00100. eCollection 2015. Review.

19.

Antibodies to probe endogenous G protein-coupled receptor heteromer expression, regulation, and function.

Gomes I, Gupta A, Bushlin I, Devi LA.

Front Pharmacol. 2014 Dec 3;5:268. doi: 10.3389/fphar.2014.00268. eCollection 2014. Review.

20.

Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers.

Fujita W, Gomes I, Dove LS, Prohaska D, McIntyre G, Devi LA.

Biochem Pharmacol. 2014 Dec 1;92(3):448-56. doi: 10.1016/j.bcp.2014.09.015. Epub 2014 Sep 28.

21.

Optimization and characterization of an opioid kappa receptor (OPRK1) antagonist.

Guerrero M, Urbano M, Brown SJ, Cayanan C, Ferguson J, Cameron M, Devi LA, Roberts E, Rosen H.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2013 Apr 15 [updated 2014 Sep 18].

22.

Salvinorin A regulates dopamine transporter function via a kappa opioid receptor and ERK1/2-dependent mechanism.

Kivell B, Uzelac Z, Sundaramurthy S, Rajamanickam J, Ewald A, Chefer V, Jaligam V, Bolan E, Simonson B, Annamalai B, Mannangatti P, Prisinzano TE, Gomes I, Devi LA, Jayanthi LD, Sitte HH, Ramamoorthy S, Shippenberg TS.

Neuropharmacology. 2014 Nov;86:228-40. doi: 10.1016/j.neuropharm.2014.07.016. Epub 2014 Aug 10.

23.

Endothelin-converting enzyme 2 differentially regulates opioid receptor activity.

Gupta A, Fujita W, Gomes I, Bobeck E, Devi LA.

Br J Pharmacol. 2015 Jan;172(2):704-19. doi: 10.1111/bph.12833. Epub 2014 Sep 5.

24.

Revolution in GPCR signalling: opioid receptor heteromers as novel therapeutic targets: IUPHAR review 10.

Fujita W, Gomes I, Devi LA.

Br J Pharmacol. 2014 Sep;171(18):4155-76. doi: 10.1111/bph.12798. Review.

25.

Opioid receptor function is regulated by post-endocytic peptide processing.

Gupta A, Gomes I, Wardman J, Devi LA.

J Biol Chem. 2014 Jul 11;289(28):19613-26. doi: 10.1074/jbc.M113.537704. Epub 2014 May 20.

26.

Hemopressin, an inverse agonist of cannabinoid receptors, inhibits neuropathic pain in rats.

Toniolo EF, Maique ET, Ferreira WA Jr, Heimann AS, Ferro ES, Ramos-Ortolaza DL, Miller L, Devi LA, Dale CS.

Peptides. 2014 Jun;56:125-31. doi: 10.1016/j.peptides.2014.03.016. Epub 2014 Apr 3.

27.

Heteromers of μ-δ opioid receptors: new pharmacology and novel therapeutic possibilities.

Fujita W, Gomes I, Devi LA.

Br J Pharmacol. 2015 Jan;172(2):375-87. doi: 10.1111/bph.12663. Epub 2014 Jul 1. Review.

28.

G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives.

Ferré S, Casadó V, Devi LA, Filizola M, Jockers R, Lohse MJ, Milligan G, Pin JP, Guitart X.

Pharmacol Rev. 2014 Feb 10;66(2):413-34. doi: 10.1124/pr.113.008052. Print 2014. Review.

29.

Cannabidiol protects liver from binge alcohol-induced steatosis by mechanisms including inhibition of oxidative stress and increase in autophagy.

Yang L, Rozenfeld R, Wu D, Devi LA, Zhang Z, Cederbaum A.

Free Radic Biol Med. 2014 Mar;68:260-7. doi: 10.1016/j.freeradbiomed.2013.12.026. Epub 2014 Jan 4.

30.

Orally active opioid μ/δ dual agonist MGM-16, a derivative of the indole alkaloid mitragynine, exhibits potent antiallodynic effect on neuropathic pain in mice.

Matsumoto K, Narita M, Muramatsu N, Nakayama T, Misawa K, Kitajima M, Tashima K, Devi LA, Suzuki T, Takayama H, Horie S.

J Pharmacol Exp Ther. 2014 Mar;348(3):383-92. doi: 10.1124/jpet.113.208108. Epub 2013 Dec 17.

31.

An integrated quantitative proteomics and systems biology approach to explore synaptic protein profile changes during morphine exposure.

Stockton SD Jr, Devi LA.

Neuropsychopharmacology. 2014 Jan;39(1):88-103. doi: 10.1038/npp.2013.227. Epub 2013 Sep 18. Review.

32.

GPR171 is a hypothalamic G protein-coupled receptor for BigLEN, a neuropeptide involved in feeding.

Gomes I, Aryal DK, Wardman JH, Gupta A, Gagnidze K, Rodriguiz RM, Kumar S, Wetsel WC, Pintar JE, Fricker LD, Devi LA.

Proc Natl Acad Sci U S A. 2013 Oct 1;110(40):16211-6. doi: 10.1073/pnas.1312938110. Epub 2013 Sep 16.

33.

Characterization of an agonist probe for opioid receptor mu 1 (OPRM1)-opioid receptor delta 1 (OPRD1) heterodimerization.

Pinello C, Guerrero M, Eberhart C, Volmar CH, Saldanha SA, Cayanan C, Urbano M, Brown SJ, Ferguson J, Gomes I, Devi LA, Roberts E, Hodder P, Rosen H.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2012 Dec 17 [updated 2013 Apr 5].

34.

Identification of a μ-δ opioid receptor heteromer-biased agonist with antinociceptive activity.

Gomes I, Fujita W, Gupta A, Saldanha SA, Negri A, Pinello CE, Eberhart C, Roberts E, Filizola M, Hodder P, Devi LA.

Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):12072-7. doi: 10.1073/pnas.1222044110. Epub 2013 Jul 1. Erratum in: Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):1760. Saldanha, Adrian S [corrected to Saldanha, S Adrian]; Eberhart, Christina [added].

35.

Disease-specific heteromerization of G-protein-coupled receptors that target drugs of abuse.

Gomes I, Fujita W, Chandrakala MV, Devi LA.

Prog Mol Biol Transl Sci. 2013;117:207-65. doi: 10.1016/B978-0-12-386931-9.00009-X. Review.

36.

Endoplasmic reticulum stress induces fibrogenic activity in hepatic stellate cells through autophagy.

Hernández-Gea V, Hilscher M, Rozenfeld R, Lim MP, Nieto N, Werner S, Devi LA, Friedman SL.

J Hepatol. 2013 Jul;59(1):98-104. doi: 10.1016/j.jhep.2013.02.016. Epub 2013 Feb 26.

37.

G-protein-coupled heteromers: regulation in disease.

Gomes I, Gupta A, Devi LA.

Methods Enzymol. 2013;521:219-38. doi: 10.1016/B978-0-12-391862-8.00012-0.

38.

Dimerization with cannabinoid receptors allosterically modulates delta opioid receptor activity during neuropathic pain.

Bushlin I, Gupta A, Stockton SD Jr, Miller LK, Devi LA.

PLoS One. 2012;7(12):e49789. doi: 10.1371/journal.pone.0049789. Epub 2012 Dec 14.

39.

Grand opening of structure-guided design for novel opioids.

Filizola M, Devi LA.

Trends Pharmacol Sci. 2013 Jan;34(1):6-12. doi: 10.1016/j.tips.2012.10.002. Epub 2012 Nov 3. Review.

40.

Structural biology: How opioid drugs bind to receptors.

Filizola M, Devi LA.

Nature. 2012 May 16;485(7398):314-7. doi: 10.1038/485314a. No abstract available.

41.

Opioid receptor heteromers in analgesia.

Costantino CM, Gomes I, Stockton SD, Lim MP, Devi LA.

Expert Rev Mol Med. 2012 Apr 10;14:e9. doi: 10.1017/erm.2012.5. Review.

42.

Cannabinoid receptor 2-mediated attenuation of CXCR4-tropic HIV infection in primary CD4+ T cells.

Costantino CM, Gupta A, Yewdall AW, Dale BM, Devi LA, Chen BK.

PLoS One. 2012;7(3):e33961. doi: 10.1371/journal.pone.0033961. Epub 2012 Mar 20.

43.

Receptor heteromerization expands the repertoire of cannabinoid signaling in rodent neurons.

Rozenfeld R, Bushlin I, Gomes I, Tzavaras N, Gupta A, Neves S, Battini L, Gusella GL, Lachmann A, Ma'ayan A, Blitzer RD, Devi LA.

PLoS One. 2012;7(1):e29239. doi: 10.1371/journal.pone.0029239. Epub 2012 Jan 3.

44.
45.

Allosteric interactions between δ and κ opioid receptors in peripheral sensory neurons.

Berg KA, Rowan MP, Gupta A, Sanchez TA, Silva M, Gomes I, McGuire BA, Portoghese PS, Hargreaves KM, Devi LA, Clarke WP.

Mol Pharmacol. 2012 Feb;81(2):264-72. doi: 10.1124/mol.111.072702. Epub 2011 Nov 9.

46.

Chronic morphine alters the presynaptic protein profile: identification of novel molecular targets using proteomics and network analysis.

Abul-Husn NS, Annangudi SP, Ma'ayan A, Ramos-Ortolaza DL, Stockton SD Jr, Gomes I, Sweedler JV, Devi LA.

PLoS One. 2011;6(10):e25535. doi: 10.1371/journal.pone.0025535. Epub 2011 Oct 17.

47.

Mice deficient in endothelin-converting enzyme-2 exhibit abnormal responses to morphine and altered peptide levels in the spinal cord.

Miller LK, Hou X, Rodriguiz RM, Gagnidze K, Sweedler JV, Wetsel WC, Devi LA.

J Neurochem. 2011 Dec;119(5):1074-85. doi: 10.1111/j.1471-4159.2011.07513.x. Epub 2011 Nov 1.

48.

Possible involvement of prolonging spinal µ-opioid receptor desensitization in the development of antihyperalgesic tolerance to µ-opioids under a neuropathic pain-like state.

Narita M, Imai S, Nakamura A, Ozeki A, Asato M, Rahmadi M, Sudo Y, Hojo M, Uezono Y, Devi LA, Kuzumaki N, Suzuki T.

Addict Biol. 2013 Jul;18(4):614-22. doi: 10.1111/j.1369-1600.2011.00354.x. Epub 2011 Aug 4.

49.

The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implications.

Miller LK, Devi LA.

Pharmacol Rev. 2011 Sep;63(3):461-70. doi: 10.1124/pr.110.003491. Epub 2011 Jul 13. Review.

50.

Potentiation of μ-opioid receptor-mediated signaling by ketamine.

Gupta A, Devi LA, Gomes I.

J Neurochem. 2011 Oct;119(2):294-302. doi: 10.1111/j.1471-4159.2011.07361.x. Epub 2011 Sep 20.

Supplemental Content

Support Center